Intrinsiqs

Is Recursion Pharmaceuticals, Inc. overvalued?

Recursion Pharmaceuticals, Inc. (RXRX) — key valuation metrics and fundamentals.

No verdict
Price
$3.19
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$1.98B
Dividend yield
0.0%
Return on equity
-47.8%
Sector
Healthcare

See the full interactive analysis →

Fair value compares RXRX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.